Madrigal Pharmaceuticals (STU:YDO1) Accounts Payable & Accrued Expense

: €92.61 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Madrigal Pharmaceuticals's quarterly accounts payable & accrued expense declined from Jun. 2023 (€86.62 Mil) to Sep. 2023 (€83.57 Mil) but then increased from Sep. 2023 (€83.57 Mil) to Dec. 2023 (€92.61 Mil).

Madrigal Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (€61.65 Mil) to Dec. 2022 (€94.80 Mil) but then declined from Dec. 2022 (€94.80 Mil) to Dec. 2023 (€92.61 Mil).

Madrigal Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Madrigal Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

19.83

34.16

61.65

94.80

92.61

Madrigal Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense																94.80	80.78	86.62	83.57	92.61

Madrigal Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Madrigal Pharmaceuticals (STU:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (STU:YDO1) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

MDGL:USA YDO1:Germany

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (STU:YDO1) Headlines

No Headlines